Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do Weight-Loss drugs alter your senses? new study investigates

NCT ID NCT07611201

Knowledge-focused Sponsor: Purdue University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from Purdue University looked at whether GLP-1 receptor agonists (like Ozempic or Wegovy) change how people taste, smell, and crave food. Researchers compared 90 adults with obesity who were either not taking the drug, or had been taking it for about 1 month or 6 months. Participants completed taste and smell tests, food preference tasks, and questionnaires. The study did not provide any medication—it only observed differences between groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help explain how GLP-1 drugs change taste and smell, potentially leading to better weight management strategies.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

90 people

The number who actually took part.

Started

Feb 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 to 65 years with a Body Mass Index (BMI) greater than 30 kg/m² will be recruited. The study population includes individuals who are eligible to take GLP-1 receptor agonists but have not yet started treatment, and individuals who have been taking GLP-1 receptor agonists for weight management for approximately 1 month or approximately 6 months as part of their regular medical care. Participants will be recruited from the general population and through healthcare providers at IU Health.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 18 to 65 years. * Any sex or gender. * Body Mass Index (BMI) \>30 kg/m². * Stable medication use, excluding weight management medications other than GLP-1 receptor agonist use as part of regular medical care. * Eligible to take GLP-1 receptor agonists but not yet started treatment, or currently taking GLP-1 receptor agonists for weight management for approximately 1 month (±0.5 months) or approximately 6 months (±0.5 months). * No known sensitivity or allergy to study solutions or foods, including sweet solutions, salty solutions, sour solutions, bitter solutions, fatty stimuli, common food flavors used in testing, milk, and fruit-flavored beverages. Exclusion Criteria: * Younger than 18 years or older than 65 years. * Previous bariatric surgery or planned bariatric surgery within the next year. * Sensitivity or allergy to study foods, taste solutions, odor stimuli, or food-related test materials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Appetite are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anosmia Feeding Behavior Food Preferences Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Appetite Eating behavior Obesity Olfaction Overweight Taste perception

Contacts and locations

Locations

  • Purdue University

    West Lafayette, Indiana, 47906, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.